02669nas a2200277 4500008004100000245012100041210006900162260001800231300001400249490000700263520179300270653002702063653001302090653001702103653001402120653001402134653002902148100002102177700002002198700002602218700003202244700001902276700003502295700002502330856003602355 2024 eng d00aPotential Molecular level Impact of Cresvin beta on Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial0 aPotential Molecular level Impact of Cresvin beta on Type 2 Diabe cDecember 2024 a1297-13040 v163 a

Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with an increasing prevalence rate over the past few decades. Despite the availability of medications to prevent and reduce disease severity, T2DM prevalence and incidence continue to rise annually. Understanding genetic heritage's impact on therapeutic responses is improving, with pharmacogenetics being used to better comprehend the therapeutic variability of T2DM. This study aims to compare the effects of metformin and Cresvin beta capsules containing Pterocarpus marsupium, Withania somnifera, Salacia reticulata, Gymnema Sylvestre, Curcuma longa, Vitis vinifera and Piper nigrum (Black pepper extract) on diabetic and immune-related gene expression in T2DM patients. Methods: Sixty patients were divided into two groups: metformintreated (group A, n=30) and Cresvin beta -treated (group B, n=30). Anthropometric, biochemical, and hematological parameters were measured at baseline and after 3 months of treatment. Gene expression levels were analyzed using quantitative real-time polymerase chain from DNA extracted from whole blood samples. Results: After 3 months, metformin significantly reduced fasting blood sugar (FBS), postprandial blood sugar (PPBS), and HbA1c levels (p<0.001). Cresvin beta also significantly reduced FBS (p<0.01), PPBS (p<0.001), and HbA1c (p<0.001). Gene expression analysis showed significant changes in SIRT1, AKT, SLC2A4, IL-6, and TNF-α in both groups. Conclusion: The study demonstrated that Cresvin beta reduced glycemic levels and improved SIRT1, Pi3k, Akt, and SLC2A4 gene expression while decreasing IL-6 and TNF-α cytokine gene expression in T2DM patients.

10aanti-diabetic efficacy10aAyurveda10aCresvin beta10aMetformin10aSirtuin 110aType 2 diabetes mellitus1 aN, Nandakumar, K1 aNehru, Mohanraj1 aSubramanian, Prasanth1 aMothiswaran, Bhuvaneshwaran1 aS, Vishagan, S1 aChandra, Satishkumar, Rajappan1 aPrabhu, Venkataraman uhttps://phcogj.com/article/2423